RecruitingObesityOverweightDiabetes Mellitus, Type 2
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eligible age
18+ yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.
Sponsor: Eli Lilly and Company
You may qualify if…
- ✓ Have type 2 diabetes
- ✓ Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
- ✓ Have a BMI of ≥27 kg/m2 at screening
- ✓ Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
You may not qualify if…
- ✕ Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- ✕ Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- ✕ Have type 1 diabetes
- ✕ Have taken any of the following within 90 days prior to screening
- ✕ medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
- ✕ dipeptidyl peptidase 4 (DPP-4) inhibitors, and
- ✕ insulin
- ✕ Have had within 90 days prior to screening:
Where it's recruiting
Arizona
Tucson
California
Escondido · Los Alamitos · Los Angeles
Colorado
Aurora
Connecticut
Waterbury
Florida
Pembroke Pines · Weston
Georgia
Dalton
Hawaii
Honolulu
Indiana
Evansville · Indianapolis
Louisiana
Eunice · Marrero
Missouri
Springfield · St Louis
New Jersey
Warren Township
New York
New York
Source: ClinicalTrials.gov · NCT07881458 · last updated 2026-11-18